Conjunctivitis in adolescent patients aged 12–17 with moderate-to-severe atopic dermatitis treated with tralokinumab up to week 52: results from the phase 3 ECZTRA 6 trial

Main Article Content

Andreas Wollenberg
Marjolein de Bruin-Weller
Jacob P Thyssen
Lisa A Beck
Eric L Simpson
Shinichi Imafuku
Mark Boguniewicz
Azra Kurbasic
Lise Soldbro
Natacha Strange Vest
Petra Arlert
Amy S Paller

Keywords

atopic dermatitis, eczema, conjunctivitis, tralokinumab, phase 3, clinical trial, safety

References

1. Weidinger S, et al. Nat Rev Dis Primers. 2018;4:1

2. Simpson EL, et al. JAMA Dermatol. 2020;156:44–56

3. Thyssen JP, et al. J Am Acad Dermatol. 2017; 77: 280–86.e28

4. Wollenberg A, et al. Br J Dermatol. 2022;186:453–65

5. Akinlade B, et al. Br J Dermatol. 2019;181:459-73

6. Bieber T. Allergy. 2020;75:54–62

7. Tsoi LC, et al. J Invest Dermatol. 2019;139:1480–89

8. Popovic B, et al. J Mol Biol. 2017;429:208–19

Most read articles by the same author(s)

1 2 3 > >>